WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
2007年9月7日 - 10:00PM
PRニュース・ワイアー (英語)
NEW YORK, Sept. 7 /PRNewswire-FirstCall/ -- Richard Gabriel, Chief
Executive Officer of DNAPrint Genomics, Inc. (OTC:DNAG) (BULLETIN
BOARD: DNAG) (http://www.dnaprint.com/) will be featured in an
exclusive interview with http://www.wallst.net/ that is scheduled
to take place on September 10 at 11 a.m. EDT. The interview will be
posted on http://www.wallst.net/ by 8 p.m. EDT on September 10. The
interview will cover topics including DNAPrint Genomics' market
potential, growth initiatives, competitive edge, recent news, and
milestones for which investors should watch. To hear the interview
in its entirety, visit http://www.wallst.net/, and click on
"Interviews." The interview can be accessed either by locating the
company's ticker symbol under the appropriate exchange at the top
of the "Interviews" section of the site, or by entering the
company's ticker symbol in the Search Archive window on the
right-hand column of the "Interviews" section. About DNAPrint
Genomics: DNAPrint(TM) Genomics, Inc. is a developer of
genomics-based products and services in two primary markets:
biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly
owned subsidiary, develops diagnostic tests and theranostic
products (drug/test combinations) using the Company's proprietary
ancestry-informed genetic marker studies combined with proprietary
computational modeling technology. Computational Biology and
Pharmacogenomics services are also offered externally to
biopharmaceutical companies. The Company's first theranostic
product is PT-401, a "Super EPO" (erythropoietin) dimer protein
drug for the treatment of anemia in renal dialysis patients (with
end stage renal disease). DNAPrint is proud of its continued
dedication to developing and supplying new technological advances
in law enforcement and consumer ancestry heritage interests. For
more information about the company, please visit
http://www.dnaprint.com/. About WallSt.net: http://www.wallst.net/
is owned and operated by WallStreet Direct, Inc., a wholly owned
subsidiary of Financial Media Group, Inc.
(http://www.financialmediagroupinc.com/). The Web site is a leading
provider of timely business news, executive interviews, multimedia
content, and research tools. Financial Media Group, Inc. also owns
http://www.mywallst.net/, a financial social network for investors,
and Financial Filings Corp. (http://www.financialfilings.com/), a
provider of media and compliance solutions to publicly traded
companies. In addition to WallSt.net, WallStreet Direct, Inc. owns
and operates WallStRadio (http://www.wallstradio.com/), a business
and finance podcast Web site. Financial Filings Corp. is expecting
to receive two hundred eighty dollars from DNAPrint Genomics, Inc.
for the dissemination of this press release. For a complete list of
our advertisers, and advertising relationships, visit
http://www.wallst.net/disclaimer/disclaimer.asp. (Logo:
http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO) Contact:
WallSt.net 800-4-WALL-ST DATASOURCE: Financial Filings Corp.
CONTACT: WallSt.net, 1-800-4-WALL-ST Web site:
http://www.financialfilings.com/ http://www.wallst.net/
http://www.dnaprint.com/
Copyright